Major risk factors for cardiovascular disease - Debunking the "only 50%" myth

[11] MORTALITY OVER A PERIOD OF 10 YEARS IN PATIENTS WITH PERIPHERAL ARTERIAL-DISEASE [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (06) : 381 - 386

[12] Mortality risk reduction associated with smoking cessation in patients with coronary heart disease - A systematic review [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (01): : 86 - 97

[13] Major risk factors as antecedents of fatal and nonfatal coronary heart disease events [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (07): : 891 - 897

[14] Emerging risk factors for atherosclerotic vascular disease - A critical review of the evidence [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (07): : 932 - 940

[15] Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (04) : 229 - 234

[16] Increasing burden of cardiovascular disease - Current knowledge and future directions for research on risk factors [J]. CIRCULATION, 1998, 97 (11) : 1095 - 1102

[17] Kannel W B, 1994, J Cardiovasc Risk, V1, P333, DOI 10.1097/00043798-199412000-00009

[18] The effect of aspirin on C-reactive protein as a marker of risk in unstable angina [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (05) : 1266 - 1270

[19] Prevalence of conventional risk factors in. patients with coronary heart disease [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (07): : 898 - 904

[20] Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization [J]. CIRCULATION, 2001, 104 (02) : 163 - 167

[11] MORTALITY OVER A PERIOD OF 10 YEARS IN PATIENTS WITH PERIPHERAL ARTERIAL-DISEASE [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (06) : 381 - 386

[12] Mortality risk reduction associated with smoking cessation in patients with coronary heart disease - A systematic review [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (01): : 86 - 97

[13] Major risk factors as antecedents of fatal and nonfatal coronary heart disease events [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (07): : 891 - 897

[14] Emerging risk factors for atherosclerotic vascular disease - A critical review of the evidence [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (07): : 932 - 940

[15] Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (04) : 229 - 234

[16] Increasing burden of cardiovascular disease - Current knowledge and future directions for research on risk factors [J]. CIRCULATION, 1998, 97 (11) : 1095 - 1102

[17] Kannel W B, 1994, J Cardiovasc Risk, V1, P333, DOI 10.1097/00043798-199412000-00009

[18] The effect of aspirin on C-reactive protein as a marker of risk in unstable angina [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (05) : 1266 - 1270

[19] Prevalence of conventional risk factors in. patients with coronary heart disease [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (07): : 898 - 904

[20] Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization [J]. CIRCULATION, 2001, 104 (02) : 163 - 167